To further explore the impact of ZSWIM4 on the response of GISTs to imatinib, which is used as the first-line targeted therapeutic drug of GISTs and its treatment efficiency is dependent on the tumor's response to the drug, the GIST cells were treated with a low concentration of imatinib. The gene discussed is ZSWIM4; the disease is neoplasm.